Editorial
Due to the ongoing research on a clinically relevant subject such as the cardiotoxic effects of oncologic drugs as exemplified by Finkelman et al. in the article "Arginine-Nitric Oxide Metabolites and Cardiac Dysfunction in Patients With Breast Cancer" [1] , we wanted to point out some of the challenges faced when trying to stratify such cardiovascular risk. An extensive report of the incidences of cardiovascular adverse effects of oncologic drugs is presented, with the main purpose of highlighting not only the risk of developing heart failure but also the importance of the associated vascular adverse effects (i.e., hypertension, venous and arterial thrombosis) experienced by patients in the post-chemotherapy phase.
The most confusing aspect of the definition of cardiotoxicity is whether only clinical, clinical and subclinical, or only subclinical events should be considered [2] . Another major clinical difficulty is related to the timing of detection of myocardial damage, since a measurement of left ventricular ejection fraction at some time point during or after therapy is clearly insufficient [3] . If a biomarker allowed us to better stratify patients, and to initiate cardioprotective therapy in those patients at the earliest sign of toxicity, new efficient interventions could substantially improve outcomes [3] .
Endothelial biomarkers are gaining interest; it is known that bevacizumab decreases endothelial nitric oxide synthase activity, which may stimulate plasminogen activator inhibitor-1 expression, leading to an increased risk of hypertension [4] . Finkelman et al. reported that plasma levels of endothelium biomarkers such as arginine, citrulline, and dimethylarginine were altered during the early phase of treatment with anthracycline-based chemotherapy [1] . As mentioned by Lenihan [3] , if the predominant mechanism of early cardiotoxicity related to anthracycline administration were actually vascular in nature, it would substantially change potential prevention and treatment strategies. The severity of these adverse effects may not present in an early catastrophic manner as it would likely happen secondary to direct cardiotoxicity (e.g., systolic dysfunction), but they could highly impact the long-term prognosis.
Herrmann J et al. proposed a Cardiotoxicity Risk Score (CRS) that included a medication-related risk depending on incidence rates of cardiotoxicity [5] . The cut-off values for these categories were >15% (high), 15% -5% (moderate), <5% (mild) and <1% (rare), which we used to categorize the risk in this brief communication. A thorough review of the literature in Dailymed (US National Library of Medicine), UpToDate® , US Food and Drug Administration (FDA) approved drug online registry and Pubmed (Medical Subject Headings terms: "Adverse effects", "Drug-related Side Effects and Adverse Reactions") was conducted, looking for incidences of cardiotoxicity of oncologic drugs. It is pertinent to mention that the heterogeneity of the information made this analysis more challenging. For e.g., the time point when cardiotoxicity becomes clinically evident varies substantially; this is the reason why different follow-up periods have been used. Furthermore, the different types of populations (e.g., naïve vs. relapse), different regimens, patient's Eastern Cooperative Oncology Group (ECOG) performance status, and disease stage and grade, add complexity to the conclusions achieved ( Table 1) . Literature is vast regarding the data here cited. Due to the nature of this brief editorial, only the most relevant references have been listed; however, the authors would be more than pleased to email the full list of sources to the readers who do require so. A-fib: atrial fibrillation; HF: heart failure; HTN: hypertension; MI: myocardial ischemia; QTc: corrected QT interval; VTE: venous thromboembolism.
TABLE 1: Reported incidences (%) of cardiovascular adverse effects of oncologic drugs
As depicted in Figure 1 , some drugs primarily affect cardiac function (i.e., anthracyclines and trastuzumab), vascular function (e.g., 5-fluorouracil and capecitabine), or both (e.g., bevacizumab and sunitinib); information concordant with current accepted and potential mechanisms [5] . Tyrosine kinase inhibitors (TKIs) present a risk of vascular damage associated with moderate (i.e., sunitinib, pazopanib, sorafenib, trametinig) or mild (i.e., levantinib, carbozantinib, ponatinib) risk of myocardium injury. Likewise, monoclonal antibodies (Ab) such as bevacizumab (VEGF Ab) and ado-trastuzumab (HER2 Ab) have a mixed effect, whereas rituximab (CD20 Ab), alemtuzumab (CD52 Ab) and daratumumab (CD38 Ab) report almost exclusive vascular adverse effects. Interestingly, some drugs, such as anthracyclines [1] , have been recently associated with vascular damage, which reveals the importance of research in identifying new biomarkers that could be used to improve cardiotoxicity risk scores.
